REG - Faron Pharma. Oy - Grant of options

Faron Pharmaceuticals OyAnnouncement

28/01/2022 07:00

For best results when printing this announcement, please click on link below:
http://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20220128:nRSb9145Za&default-theme=true

RNS Number : 9145Z  Faron Pharmaceuticals Oy  28 January 2022

Faron Pharmaceuticals Ltd

("Faron" or the "Company")

 

Grant of Options

 

Company announcement, January 28, 2022 at 09:00 AM (EET) / 07:00 AM (GMT) /
02:00 AM (EDT)

 

TURKU, FINLAND / BOSTON, MA - Faron Pharmaceuticals Ltd (AIM: FARN, First
North: FARON), a clinical stage biopharmaceutical company focused on building
the future of immunotherapy by harnessing the power of the immune system to
tackle cancer and inflammation, announces that the Board of Faron has granted
100,000 options over ordinary shares in the Company ("Options") under the
Faron 2019 Option Plan to Dr. Marie-Louise Fjällskog, who was appointed as
Faron's new Chief Medical Officer on January 3, 2022. The Options have been
allocated under the U.S. Sub-Plan of Faron's 2019 Option Plan and are
exercisable between 17 November 2022 and 17 November 2026 at an exercise price
of €4.04 per share, vesting 25% per annum over a period of four years. The
exercise price is calculated based on the average share price per share at
which the Company's ordinary shares have been traded on AIM over a period of
30 days immediately preceding the grant date. The terms of the 2019 Option
Plan are available on the Company's website.

 

The granted 100,000 Options entitle the option holder to subscribe for a total
of 100,000 new ordinary shares in the Company, if exercised in full, and
represent 0.19% of the fully-diluted ordinary share capital of the Company.

 

 

For more information please contact:

 

Media Contact

Faron Pharmaceuticals

Eric Van Zanten

Head of Communications

eric.vanzanten@faron.com (mailto:Eric.vanzanten@faron.com)

Investor.relations@faron.com

Phone: +1 (610) 529-6219

 

Investor Contact

Stern Investor Relations

Julie Seidel

julie.seidel@sternir.com (mailto:Julie.seidel@sternir.com)

Phone: +1 (212) 362-1200

 

Cairn Financial Advisers LLP, Nomad

Sandy Jamieson, Jo Turner

Phone: +44 (0) 207 213 0880

 

Peel Hunt LLP, Broker

Christopher Golden, James Steel

Phone: +44 (0) 20 7418 8900

 

Sisu Partners Oy, Certified Adviser on Nasdaq First North

Juha Karttunen

Phone: +358 (0)40 555 4727

Jukka Järvelä

Phone: +358 (0)50 553 8990

 

Consilium Strategic Communications

Mary-Jane Elliott, David Daley, Lindsey Neville

faron@consilium-comms.com (mailto:faron@consilium-comms.com)

Phone: +44 (0)20 3709 5700

 

 

About Faron Pharmaceuticals Ltd

Faron (AIM: FARN, First North: FARON) is a clinical stage biopharmaceutical
company developing novel treatments for medical conditions with significant
unmet needs caused by dysfunction of our immune system. The Company currently
has a pipeline based on the receptors involved in regulation of immune
response in oncology, organ damage and bone marrow regeneration. Bexmarilimab,
a novel anti-Clever-1 humanized antibody, is its investigative precision
immunotherapy with the potential to provide permanent immune stimulation for
difficult-to-treat cancers through targeting myeloid function. Currently in
Phase I/II clinical development as a potential therapy for patients with
untreatable solid tumors, bexmarilimab has potential as a single-agent therapy
or in combination with other standard treatments including immune checkpoint
molecules. Traumakine is an investigational intravenous (IV) interferon
beta-1a therapy for the treatment of acute respiratory distress syndrome
(ARDS) and other ischemic or hyperinflammatory conditions. Traumakine is
currently being evaluated in global trials as a potential treatment for
hospitalized patients with COVID-19 and with the 59th Medical Wing of the US
Air Force and the US Department of Defense for the prevention of multiple
organ dysfunction syndrome (MODS) after ischemia-reperfusion injury caused by
a major trauma.  Faron is based in Turku, Finland. Further information is
available at www.faron.com (http://www.faron.com/) .

 

 Notification of a Transaction pursuant to Article 19(1) of Regulation (EU) No.
 596/2014
 1   Details of the person discharging managerial responsibilities/person closely
     associated
 a.  Name                                                         Marie-Louise Fjällskog
 2   Reason for notification

 a.  Position/Status                                              Person discharging managerial responsibilities
 b.  Initial notification/                                        Initial Notification

     Amendment
 3   Details of the issuer, emission allowance market participant, auction
     platform, auctioneer or auction monitor
 a.  Name                                                         Faron Pharmaceuticals Oy
 b.  LEI                                                          7437009H31TO1DC0EB42
 4   Details of the transaction(s): section to be repeated for (i) each type of
     instrument; (ii) each type of transaction; (iii) each date; and (iv) each
     place where transactions have been conducted
 a.  Description of the financial instrument, type of instrument  Options over ordinary shares

Identification Code
ISIN: FI4000153309
 b.  Nature of the transaction                                    Grant of options made pursuant to the Faron 2019 Option Plan exercisable at
                                                                  EUR 4,04 per Ordinary Share
 c.  Price(s) and volume(s)
                                                                               Price(s)       Volume(s)

 100,000
     Nil

 d.  Aggregated information

     - Aggregated Volume                                          100,000

     - Price                                                      Nil

 e.  Date of the transaction                                      January 27, 2022
 f.  Place of the transaction                                     Turku

 

 

d.

Aggregated information

 

- Aggregated Volume

 

- Price

 

 

100,000

 

Nil

 

 

e.

Date of the transaction

January 27, 2022

f.

Place of the transaction

Turku

 

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  DSHBKOBQDBKBADB